Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity

Toxicology and Applied Pharmacology

Volumn 200, Issue 2, 2004, Pages 159-168

  Oliveira, Paulo J ^a   Bjork, James A ^b   Santos, Maria S ^a   Leino, Richard L ^b   Froberg, M Kent ^b   Moreno, António J ^a   Wallace, Kendall B ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

; Atenolol; Carvedilol; DMSO; DOX; Doxorubicin; doxorubicin; Heart; Mitochondria; mitochondrial transmembrane potential; Mitochondrionopathy; Oxidative damage; Permeability transition pore; tetraphenylphosphonium cation; TPP +

Indexed keywords

ANTIOXIDANT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DOXORUBICIN; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENERGY; HEART MITOCHONDRION; HISTOPATHOLOGY; MALE; MITOCHONDRIAL TOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTECTION; RAT; TISSUE SLICE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CALCIUM; CARBAZOLES; CARDIOMYOPATHIES; CELL SURFACE EXTENSIONS; DOXORUBICIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; ION CHANNELS; MALE; MICROSCOPY, ELECTRON; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; ONIUM COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; OXYGEN CONSUMPTION; PROPANOLAMINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 5144227343     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2004.04.005     Document Type: Article

References (42)

1. Abiko Y., Gotoh H., Yokoyama T., Abiko T., Hashizume H., Akiyama K. Bopindolol and its metabolite 18-053 attenuate regional myocardial acidosis during partial occlusion of the coronary artery in dogs. Arch. Int. Pharmacodyn. Ther. 327:1994;40-55
2. Bernardi P. Mitochondrial transport of cations: channels exchangers and permeability transition. Physiol. Rev. 79:1999;1127-1155
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254
4. Broekemeier K.M., Dempsey M.E., Pfeiffer D.R. Cyclosporin a is a potent inhibitor of the inner membrane mitochondrial transition in liver mitochondria. J. Biol. Chem. 264:1989;7826-7830
5. Chacon E., Ulrich R., Acosta D. A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes. Biochem. J. 281:1992;871-878
6. Chernyak B.V., Bernardi P. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur. J. Biochem. 238:1996;623-630
7. DeAtley S.M., Aksenov M.Y., Aksenova M.V., Harris B., Hadley R., Harper P.C., Carney J.M., Butterfield D.A. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 136:1999;41-46
8. Demant E.J.F. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem. Pharmacol. 41:1991;543-552
9. Doroshow J.H. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 43:1983;4543-4551
10. Estabrook R.W. Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios. Methods Enzymol. 10:1967;41-47
11. Hall S., Prescott R.I., Hallman R.J., Dixon S., Harvey R.E., Ball R.G. A comparative study of carvedilol, slow release nifedipine, and atenolol in the management of essential hypertension. J. Cardiovasc. Pharmacol. 18(Suppl. 4):1991;S35-S38
12. Hrdina R., Gersl V., Klimtová I., Simunek T., Machá cková J., Adamcová M. Anthracycline-induced cardiomyopathy. Acta Med. 43:2000;75-82
13. Iwasaki T., Suzuki T. Ultrastructural alterations of the myocardium induced by doxorubicin. Virchows Arch. B Cell Pathol. 60:1991;35-39
14. Jones D.P. Determination of pyridine dinucleotides in cell extracts by high-performance liquid chromatography. J. Chromatography. 225:1981;446-449
15. Kamo N., Muratsugu M., Hongoh R., Kobatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 49:1979;105-121
16. Kotsinas A., Gorgoulis V., Zacharatos P., Zioris H., Triposkiadis F., Donta I., Kyriakidis M., Karayannacos P., Kittas C. Antioxidant agent nimesulid and β-blocker metoprolol do not exert protective effects against rat mitochondrial DNA alterations in adriamycin-induced cardiotoxicity. Biochem. Biophys. Res. Commun. 254:1999;651-656
17. Kowaltowski A.J., Vercesi A.E. Mitochondrial damage induced by conditions of oxidative stress. Free Radical Biol. Med. 26:1999;463-471
18. Lee V., Randhawa A., Singal P.K. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am. J. Physiol. 261:1991;H989-H995
19. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.-G., Ahn B.-W., Shaltiel S., Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186:1990;464-478
20. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 65:1999;1265-1274
21. McTavish D., Campoli-Richards D., Sorkin E.M. Carvedilol, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 45(2):1993;232-258
22. Mimnaugh E.G., Trush M.A., Bhatnagar M., Gram T.E. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol. 34:1985;847-856
23. Monti E., Cova D., Guido E., Morelli R., Oliva C. Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radical Biol. Med. 21:1996;463-470
24. Noguchi N., Nishino K., Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol. 59:2000;1069-1076
25. Oliveira P.J., Santos D.L., Moreno A.J.M. Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch. Biochem. Biophys. 374:2000;279-285
26. Oliveira P.J., Coxito P.M., Rolo A.P., Santos D.L., Palmeira C.M., Moreno A.J.M. Inhibitory effect of carvedilol in the high-conductance state of the mitochondrial permeability transition pore. Eur. J. Pharmacol. 412:2001;231-237
27. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4:1990;3076-3086
28. Palmeira C.M., Serrano J., Kuehl D.W., Wallace K.B. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim. Biophys. Acta. 1321:1997;101-106
29. Papadopoulou L.C., Theophilidis G., Thomopoulos G.N., Tsiftsoglou A.S. Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem. Pharmacol. 57:1999;481-489
30. Petronilli V., Constantini P., Scorrano L., Colonna R., Passamonti S., Bernardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. J. Biol. Chem. 269:1994;16638-16642
31. Prohaska J.R. Changes in tissue growth, concentrations of copper, iron, cytochrome oxidase and superoxide dismutase subsequent to dietary or genetic copper deficiency in mice. J. Nutr. 113:1983;2048-2058
32. 2+ concentrations associated with glutamate excitotoxicity in cultured rat brain neurons. Neurosci. Lett. 162:1993;149-152
33. Santos D.L., Moreno A.J.M., Leino R.L., Froberg M.K., Wallace K.B. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol. Appl. Pharmacol. 185:2002;218-227
34. 2+ from rat heart mitochondria-induction by adriamycin aglycone. Biochem. Pharmacol. 37:1988;803-812
35. Solem L.E., Henry T.R., Wallace K.B. Disruption of mitochondrial calcium homeostasis in vivo following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129:1994;214-222
36. Solem L.E., Heller L.J., Wallace K.B. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J. Mol. Cell. Cardiol. 28:1996;1023-1032
37. Van Vleet J.F., Ferrans V.J., Weirich W.E. Cardiac disease induced by chronic adriamycin administration in dogs and evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 99:1980;13-42
38. Xu M.F., Tang P.L., Qian Z.M., Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 68:2001;889-901
39. Yin X., Wu H., Chen Y., Kang Y.J. Induction of antioxidants by adriamycin in mouse heart. Biochem. Pharmacol. 56:1998;87-93
40. Yue T.-L., McKenna P.J., Ruffolo R.R. Jr., Feuerstein G. Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur. J. Pharmacol. 214:1992;277-280
41. Zhou S., Heller L.J., Wallace K.B. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol. Appl. Pharmacol. 175:2001;60-67
42. Zhou S., Starkov A., Froberg M.K., Leino R.L., Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61:2001;771-777